Xeris Biopharma Inc. (XERS)
| Bid | 3.3 |
| Market Cap | 690.42M |
| Revenue (ttm) | 203.07M |
| Net Income (ttm) | -54.84M |
| EPS (ttm) | -0.37 |
| PE Ratio (ttm) | -12.12 |
| Forward PE | 38.12 |
| Analyst | Strong Buy |
| Ask | 5.64 |
| Volume | 1,530,842 |
| Avg. Volume (20D) | 3,070,455 |
| Open | 4.58 |
| Previous Close | 4.57 |
| Day's Range | 4.38 - 4.60 |
| 52-Week Range | 1.72 - 6.07 |
| Beta | 0.89 |
About XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...
Analyst Forecast
According to 5 analyst ratings, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $6, which is an increase of 33.78% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve ...
